Abstract:Senescence refers to a cellular state featuring a stable cell‐cycle arrest triggered in response to stress. This response also involves other distinct morphological and intracellular changes including alterations in gene expression and epigenetic modifications, elevated macromolecular damage, metabolism deregulation, and a complex proinflammatory secretory phenotype. The initial demonstration of oncogene‐induced senescence in vitro established senescence as an important tumour suppressive mechanism, in addition to apoptosis. Senescence not only halts the proliferation of premalignant cells but also facilitates the clearance of affected cells through immunosurveillance. Failure to clear senescent cells owing to deficient immunosurveillance may, however, lead to a state of chronic inflammation that nurtures a pro‐tumorigenic microenvironment favouring cancer initiation, migration, and metastasis. In addition, senescence is a response to post‐therapy genotoxic stress. Therefore, tracking the emergence of senescent cells becomes pivotal to detect potential pro‐tumorigenic events. Current protocols for the in vivo detection of senescence require the analysis of fixed or deep‐frozen tissues, despite a significant clinical need for real‐time bioimaging methods. Accuracy and efficiency of senescence detection is further hampered by a lack of universal and more specific senescence biomarkers. Recently, in an attempt to overcome these hurdles, an assortment of detection tools have been developed. These strategies all have significant potential for clinical utilization, and include flow cytometry combined with histo‐ or cytochemical approaches, nanoparticle‐based targeted delivery of imaging contrast agents, OFF‐ON fluorescent senoprobes, positron emission tomography (PET) senoprobes, and analysis of circulating SASP factors, extracellular vesicles, and cell‐free nucleic acids isolated from plasma. Here we highlight the occurrence of senescence in neoplasia and advanced tumours, assess the impact of senescence on tumorigenesis, and discuss how the ongoing development of senescence detection tools might improve early detection of multiple cancers and response to therapy in the near future.

Brief guide to senescence assays using cultured mammalian cells

Guidelines for minimal information on cellular senescence experimentation in vivo

Cellular Senescence: Mechanisms, Morphology, and Mouse Models

Cellular Senescence: Defining a Path Forward

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Cellular aging beyond cellular senescence: Markers of senescence prior to cell cycle arrest in vitro and in vivo

Cellular senescence: the good, the bad and the unknown

Simple Detection Methods for Senescent Cells: Opportunities and Challenges

Biomarkers of Cellular Senescence and Aging: Current State-of-the-Art, Challenges and Future Perspectives

SenNet recommendations for detecting senescent cells in different tissues

Cellular Senescence: Mechanisms and Therapeutic Potential

Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs

Cellular senescence in cancer: from mechanisms to detection

Seeking for cellular senescence associated genes

Cellular senescence in vivo: From cells to tissues to pathologies

Recent Developments in Small-Molecule Fluorescent Probes for Cellular Senescence

Developing transcriptomic signatures as a biomarker of cellular senescence

Senescence detection using reflected light

Shining The Light On Senescence Associated Lncrnas

The power of proteomics to monitor senescence-associated secretory phenotypes and beyond: toward clinical applications

SenePy: Unveiling the Cell-Type Specific Landscape of Cellular Senescence through Single-Cell Analysis in Living Organisms